Elsevier Launches New Journal: Performance Enhancement & Health
Sydney, August 16, 2012 – Elsevier, a world-leading provider of scientific, technical, and medical information products and services, is proud to announce the launch of Performance Enhancement & Health – a new international, peer-reviewed journal that critically explores the health implications of performance enhancement on the human being, from steroid doping in elite athletes, right through to amphetamine use amongst truck drivers.
Performance Enhancement & Health boasts a wide-ranging appeal that extends from social scientists through to healthcare workers and, of course, those working in physical or sporting fields. As a multidisciplinary journal it provides fascinating food for thought. With the 2012 Olympic Games only just ended, the debate continues over performance enhancement in sport.
Performance enhancement is not only unique to athletes however. Performance enhancement can be pharmacological, genetic, psychological or technological and may be linked to identity, social capital or pleasure, as well as productivity. Health is envisaged broadly as absence of disease, optimal functioning, and (personal or community) well-being. Performance Enhancement & Health therefore examines the implications of performance enhancement on the human condition – both in the sporting arena and beyond.
The journal’s co-editors, Dr Jason Mazanov of the University of New South Wales and Associate Professor Frances Quirk of James Cook University, identified the need for a specific forum for scholars to discuss the role and impact of performance enhancement in society.
Mazanov and Quirk’s aims in producing Performance Enhancement & Health include exploring how the effort to enhance our human condition has influenced health, and developing a more worldly understanding of the performance enhancement–health nexus.
The first two issues of Performance Enhancement & Health (published in the remainder of 2012) are freely available. In 2013, the journal, consisting of 4 issues, can be ordered online at http://www.elsevier.com/wps/find/journaldescription.cws_home/725634/bibliographic
For more information or to submit and article, go to: Performance Enhancement & Health.
The first articles to be published in the journal are now available on ScienceDirect.
# # #
About the Co-Editors-in-Chief
Dr Jason Mazanov
Dr Jason Mazanov is a senior lecturer and registered psychologist. He works at the University of New South Wales’ ADFA campus in Canberra, ACT, Australia. Dr Mazanov’s fields of research include sport and exercise psychology, sport and leisure management and sports medicine, with his primary research involving understanding the management of drugs in sport.
Associate Professor Frances Quirk
Frances Quirk is the head of discipline and associate professor in mental health within the School of Medicine and Dentistry at James Cook University in Townsville, QLD, Australia. She is also the deputy chair of the academic board. Her research interests include the ‘potential of integrating physical and mental health indicators for this holistic approach and response to a broad range of disorders.’
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media contact
+61 29422 8550